Relationship Between Renal Function and the Incidence of Adverse Events in Patients With Colorectal Cancer Receiving Oxaliplatin

被引:9
|
作者
Watanabe, Daichi [1 ]
Fujii, Hironori [1 ]
Yamada, Yunami [1 ]
Iihara, Hirotoshi [1 ]
Ishihara, Takuma [2 ]
Matsuhashi, Nobuhisa [3 ]
Takahashi, Takao [3 ]
Yoshida, Kazuhiro [3 ]
Suzuki, Akio [1 ]
机构
[1] Gifu Univ Hosp, Dept Pharm, Yanagido 1-1, Gifu 5011194, Japan
[2] Gifu Univ, Gifu Univ Hosp, Innovat & Clin Res Promot Ctr, Gifu, Japan
[3] Gifu Univ, Dept Surg Oncol, Grad Sch Med, Gifu, Japan
关键词
Oxaliplatin; creatinine clearance; adverse events; colorectal cancer; nausea; CAPECITABINE PLUS OXALIPLATIN; III COLON-CANCER; PHASE-III; 1ST-LINE TREATMENT; ADJUVANT TREATMENT; FLUOROURACIL; LEUCOVORIN; PHARMACOKINETICS; THERAPY; CHEMOTHERAPY;
D O I
10.21873/anticanres.13953
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: To clarify whether renal dysfunction affects the incidence of adverse events associated with oxaliplatin, the present study was designed to investigate the relationship between creatinine clearance (Ccr) and the incidence of oxaliplatin-related adverse events. Patients and Methods: A total of 287 CRC patients who received the first cycle of oxaliplatin-based chemotherapy were eligible. Adverse events, including nausea, vomiting, neutropenia and thrombocytopenia, were graded, and the relationship between Ccr and the incidence of adverse events was examined using multivariable logistic regression analysis. Results: A multivariable analysis indicated that the incidence of grade >= 2 nausea increased, while the incidence of other adverse events tended to be higher, as the Ccr decreased. Particularly, renal dysfunction (Ccr <60 ml/min) was a significant risk factor for grade >= 2 nausea (p=0.042). Conclusion: Care should be taken to avoid adverse events associated with oxaliplatin in patients with renal dysfunction.
引用
收藏
页码:299 / 304
页数:6
相关论文
共 50 条
  • [31] Relationship between polypharmacy and adverse events
    Mabuchi, Takayuki
    Hosomi, Kouichi
    Yokoyama, Satoshi
    Takada, Mitsutaka
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2021, 59 (05) : 353 - 357
  • [32] Dermatologic adverse events in breast cancer patients receiving endocrine therapies.
    Freites-Martinez, Azael
    Belum, Viswanath Reddy
    Geller, Shamir
    Skripnik, Anna
    Ciccolini, Kathryn
    Shapiro, Jerry
    Kitts, Sarah
    Goldfarb, Shari Beth
    Lacouture, Mario E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] Adverse Events in Pediatric Cancer Patients Receiving Sorafenib or Sorafenib Plus Irinotecan
    Yokosuka, Tomoko
    Nakamura, Wataru
    Hayashi, Akiko
    Fujita, Sachio
    Miyagawa, Naoyuki
    Iwasaki, Fuminori
    Hamanoue, Satoshi
    Goto, Shoko
    Goto, Hiroaki
    PEDIATRIC BLOOD & CANCER, 2018, 65 : S90 - S90
  • [34] Evaluation of vascular pain in patients with colorectal cancer receiving peripheral venous chemotherapy with or without oxaliplatin
    Taisuke Matsuoka
    Yoichiro Yoshida
    Naoya Aisu
    Teppei Yamada
    Ai Mogi
    Akira Komono
    Ryohei Sakamoto
    Daibo Kojima
    Gumpei Yoshimatsu
    Fumiaki Kiyomi
    Shohta Kodama
    Suguru Hasegawa
    Scientific Reports, 9
  • [35] Evaluation of vascular pain in patients with colorectal cancer receiving peripheral venous chemotherapy with or without oxaliplatin
    Matsuoka, Taisuke
    Yoshida, Yoichiro
    Aisu, Naoya
    Yamada, Teppei
    Mogi, Ai
    Komono, Akira
    Sakamoto, Ryohei
    Kojima, Daibo
    Yoshimatsu, Gumpei
    Kiyomi, Fumiaki
    Kodama, Shohta
    Hasegawa, Suguru
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [36] Relationship Between the GesEPOC 2021 Classification of Risk Levels and Phenotypes and the Incidence of Adverse Events
    Golpe, Rafael
    Marco Figueira-Goncalves, Juan
    Esteban, Cristobal
    Antonio Amado-Diago, Carlos
    Aramburu, Amaia
    Garcia-Talavera, Ignacio
    Veiga, Iria
    ARCHIVOS DE BRONCONEUMOLOGIA, 2022, 58 (05): : 451 - 453
  • [37] Relationship between occupational sunlight exposure and the incidence of renal cancer
    Jang, Hyun-Suk
    Leem, Jong-Han
    Jeon, Seong Soo
    Park, Shin-Goo
    Lee, Sangyoon
    Kang, Yangwon
    Choi, Go
    Kim, Hyung Doo
    Ju, Hyeonwoo
    Jang, Sung Wook
    Won, Youna
    Kim, Hwan-Cheol
    ANNALS OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE, 2019, 31
  • [38] Impact of renal function in the incidence of major adverse cardiovascular events following acute coronary syndromes
    Lourenco, C. N.
    Teixeira, R.
    Monteiro, S.
    Antonio, N.
    Baptista, R.
    Jorge, E.
    Monteiro, P.
    Goncalves, L.
    Freitas, M.
    Providencia, L. A.
    EUROPEAN HEART JOURNAL, 2008, 29 : 748 - 748
  • [39] A meta-analytic comparison of the incidence of adverse events for capecitabine and comparators for breast and colorectal cancer
    Reynolds, Matthew W.
    Crean, Sheila
    Fahrbach, Kyle
    Sercus, Brian
    Zelt, Susan
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 : S181 - S182
  • [40] Relationship between INR and adverse events in patients treated at an anticoagulation clinic
    Snow, R
    LaLonde, M
    Jennings, M
    Knoell, K
    Hindman, L
    Hyek, M
    Caulin-Glaser, T
    CIRCULATION, 2004, 109 (20) : E265 - E265